Literature DB >> 2718208

Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia.

K Tanaka1, F Gotoh, Y Fukuuchi, T Amano, D Uematsu, J Kawamura, T Yamawaki, N Itoh, K Obara, K Muramatsu.   

Abstract

We evaluated the effects of cilostazol, a selective inhibitor of cyclic adenosine monophosphate phosphodiesterase, on the pial vessels of adult cats subjected to endothelial damage followed by middle cerebral artery occlusion. Six cats were treated with cilostazol and four with 30% N,N-dimethylformamide in 70% saline (solvent). The brain surface was irradiated with ultraviolet rays through a cranial window for 3 minutes to selectively damage the endothelium of the pial vessels in both groups. Beginning 32 minutes after termination of the irradiation, the middle cerebral artery was occluded for 30 minutes. Thirty minutes before occlusion, intravenous infusion of 30 micrograms/kg/min cilostazol or 0.1 ml/kg/min solvent was begun and continued until the end of the study. Before occlusion, the infusion of cilostazol induced a significant (p less than 0.05) dilatation while the infusion of solvent produced no significant changes in the diameter of the pial arteries. The pial veins of solvent-treated cats showed significant (p less than 0.05) constriction during occlusion, whereas cilostazol-treated cats exhibited only mild constriction of the pial veins. The formation of platelet thrombi after occlusion was significantly (p less than 0.05) inhibited in the pial veins of cilostazol-treated compared with solvent-treated cats. Similarly, the microcirculation of the pial veins was effectively restored after reopening of the middle cerebral artery in cilostazol-treated compared with solvent-treated cats. Our data suggest that cilostazol is an effective antithrombotic agent as well as a potent vasodilator acting on vascular smooth muscle.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2718208     DOI: 10.1161/01.str.20.5.668

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  18 in total

1.  Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study.

Authors:  Shu-Yu Tai; Chen-Yu Chien; Yu-Han Chang; Yuan-Han Yang
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

Review 2.  Clinical efficacy and safety of cilostazol: a critical review of the literature.

Authors:  Kelly C Rogers; Carrie S Oliphant; Shannon W Finks
Journal:  Drugs       Date:  2015-03       Impact factor: 9.546

3.  Restoration of the cAMP second messenger pathway enhances cardiac preservation for transplantation in a heterotopic rat model.

Authors:  D Pinsky; M Oz; H Liao; S Morris; J Brett; R Sciacca; M Karakurum; M Van Lookeren Campagne; J Platt; R Nowygrod
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

4.  Cilostazol prevents progression of asymptomatic carotid artery stenosis in patients with contralateral carotid artery stenting.

Authors:  T Kato; H Sakai; T Takagi; Y Nishimura
Journal:  AJNR Am J Neuroradiol       Date:  2012-02-09       Impact factor: 3.825

5.  Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke.

Authors:  Jian-Jun Guo; En Xu; Qing-Yuan Lin; Guo-Ling Zeng; Hai-Feng Xie
Journal:  Neurosci Bull       Date:  2009-12       Impact factor: 5.203

6.  In vivo effect of visible light on feline cortical microcirculation.

Authors:  H Bertalanffy; T Kawase; S Toya
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

7.  Cilostazol suppresses neointimal hyperplasia in canine vein grafts.

Authors:  Fabio A Kudo; Yuka Kondo; Akihito Muto; Keiko Miyazaki; Alan Dardik; Masayasu Nishibe; Toshiya Nishibe
Journal:  Surg Today       Date:  2009-02-07       Impact factor: 2.549

8.  Cilostazol induces cellular senescence and confers resistance to etoposide-induced apoptosis in articular chondrocytes.

Authors:  Kang Mi Kim; Jong Min Kim; Young Hyun Yoo; Jeung Il Kim; Young Chul Park
Journal:  Int J Mol Med       Date:  2012-01-23       Impact factor: 4.101

9.  Cilostazol protects endothelial cells against lipopolysaccharide-induced apoptosis through ERK1/2- and P38 MAPK-dependent pathways.

Authors:  Jong-Hoon Lim; Jae-Suk Woo; Yung-Woo Shin
Journal:  Korean J Intern Med       Date:  2009-06-08       Impact factor: 3.165

10.  Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke.

Authors:  Shaheen E Lakhan; Annette Kirchgessner; Deborah Tepper; Aidan Leonard
Journal:  Front Neurol       Date:  2013-04-03       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.